fbpx
Wikipedia

Zoledronic acid

Zoledronic acid, also known as zoledronate and sold under the brand name Zometa by Novartis among others, is a medication used to treat a number of bone diseases. These include osteoporosis, high blood calcium due to cancer, bone breakdown due to cancer, Paget’s disease of bone and Duchenne muscular dystrophy (DMD). It is given by injection into a vein.

Zoledronic acid
Clinical data
Trade namesReclast, Zometa, others
Other nameszoledronate
AHFS/Drugs.comMonograph
MedlinePlusa605023
License data
Pregnancy
category
  • AU: B3
Routes of
administration
Intravenous
Drug classBisphosphonate
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding22%
MetabolismNil
Eliminationhalf-life146 hours
ExcretionKidney (partial)
Identifiers
  • [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
CAS Number
PubChemCID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC5H10N2O7P2
Molar mass272.090 g·mol−1
3D model (JSmol)
  • O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O
  • InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)
  • Key:XRASPMIURGNCCH-UHFFFAOYSA-N
NY (what is this?)(verify)

Common side effects include fever, joint pain, high blood pressure, diarrhea, and feeling tired. Serious side effects may include kidney problems, low blood calcium, and osteonecrosis of the jaw. Use during pregnancy may result in harm to the baby. It is in the bisphosphonate family of medications. It works by blocking the activity of osteoclast cells and thus decreases the breakdown of bone.

Zoledronic acid was patented in 1986 and approved for medical use in the United States in 2001. It is on the World Health Organization's List of Essential Medicines.

Contents

Bone complications of cancer

Zoledronic acid is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer, as well as for treating osteoporosis. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases.

It can be given at home rather than in hospital. Such use has shown safety and quality-of-life benefits in people with breast cancer and bone metastases.

Osteoporosis

Zoledronic acid, in brand name products Aclasta and Reclast among others, may be given as a 5 mg infusion once per year for treatment of osteoporosis in men and post-menopausal women at increased risk of fracture.

In 2007, the U.S. Food and Drug Administration (FDA) also approved it for the treatment of postmenopausal osteoporosis.

Other

Zoledronic acid may be used for treatment of osteogenesis imperfecta.

A single 5 mg dose of zoledronic acid is used for the treatment of Paget's disease.

‹The template below is included via a redirect (Template:Mcn) that has been nominated for discussion. See redirects for discussion to help reach a consensus on what to do.›

[medical citation needed]

Side effects can include fatigue, anemia, muscle aches, fever, and/or swelling in the feet or legs. Flu-like symptoms are common after the first infusion, although not subsequent infusions, and are thought to occur because of its potential to activate human γδ T cells (gamma/delta T cells).

Kidneys

There is a risk of severe renal impairment. Appropriate hydration is important prior to administration, as is adequate calcium and vitamin D intake prior to Aclasta therapy in patients with preexisting hypocalcaemia, and for ten days following Aclasta in patients with Paget's disease of the bone. Monitoring for other mineral metabolism disorders and the avoidance of invasive dental procedures for those who develop osteonecrosis of the jaw is recommended.

Zoledronate is rapidly processed via the kidneys; consequently its administration is not recommended for patients with reduced renal function or kidney disease. Some cases of acute kidney injury either requiring dialysis or having a fatal outcome following Reclast use have been reported to the U.S. Food and Drug Administration (FDA). This assessment was confirmed by the European Medicines Agency (EMA), whose Committee for Medicinal Products for Human Use (CHMP) specified new contraindications for the medication on 15 December 2011, which include hypocalcaemia and severe renal impairment with a creatinine clearance of less than 35 ml/min.

Bone

Osteonecrosis of the jaw

A rare complication that has been recently observed in cancer patients being treated with bisphosphonates is osteonecrosis of the jaw. This has mainly been seen in patients with multiple myeloma treated with zoledronic acid who have had dental extractions.

Atypical fractures

After approving the drug on 8 July 2009, the European Medicines Agency conducted a class review of all bisphosphonates, including zoledronic acid, after several cases of atypical fractures were reported. In 2008, the EMA's Pharmacovigilance Working Party (PhVWP) noted that alendronic acid was associated with an increased risk of atypical fracture of the femur that developed with low or no trauma. In April 2010, the PhVWP noted that further data from both the published literature and post-marketing reports were now available which suggested that atypical stress fractures of the femur may be a class effect. The European Medicines Agency then reviewed all case reports of stress fractures in patients treated with bisphosphonates, relevant data from the published literature, and data provided by the companies which market bisphosphonates. The Agency recommended that doctors who prescribe bisphosphonate-containing medicines should be aware that atypical fractures may occur rarely in the femur, especially after long-term use, and that doctors who are prescribing these medicines for the prevention or treatment of osteoporosis should regularly review the need for continued treatment, especially after five or more years of use.

Zoledronic acid slows down bone resorption, allowing the bone-forming cells time to rebuild normal bone and allowing bone remodeling.

Relative potency
Bisphosphonate Relative potency
Etidronate 1
Tiludronate 10
Pamidronate 100
Alendronate 100-500
Ibandronate 500-1000
Risedronate 1000
Zoledronate 5000

Zoledronic acid has been found to have a direct antitumor effect and to synergistically augment the effects of other antitumor agents in osteosarcoma cells.

Zoledronic acid has shown significant benefits versus placebo over three years, with a reduced number of vertebral fractures and improved markers of bone density. An annual dose of zoledronic acid may also prevent recurring fractures in patients with a previous hip fracture.

Zoledronic acid also attenuates accumulation of DNA damage in mesenchymal stem cells and protects their function.

With hormone therapy for breast cancer

An increase in disease-free survival (DFS) was found in the ABCSG-12 trial, in which 1,803 premenopausal women with endocrine-responsive early breast cancer received anastrozole with zoledronic acid. A retrospective analysis of the AZURE trial data revealed a DFS survival advantage, particularly where estrogen had been reduced.

In a meta-analysis of trials where upfront zoledronic acid was given to prevent aromatase inhibitor-associated bone loss, active cancer recurrence appeared to be reduced.

As of 2010[update] "The results of clinical studies of adjuvant treatment on early-stage hormone-receptor-positive breast-cancer patients under hormonal treatment – especially with the bisphosphonate zoledronic acid – caused excitement because they demonstrated an additive effect on decreasing disease relapses at bone or other sites. A number of clinical and in vitro and in vivo preclinical studies, which are either ongoing or have just ended, are investigating the mechanism of action and antitumoral activity of bisphosphonates."

A 2010 review concluded that "adding zoledronic acid 4 mg intravenously every 6 months to endocrine therapy in premenopausal women with hormone receptor-positive early breast cancer ... is cost-effective from a US health care system perspective".

  1. Drugs.com International trade names for zoledronic acid Page accessed Jan 14, 2015
  2. "Zoledronic acid Use During Pregnancy". Drugs.com. 1 June 2020. Retrieved19 October 2020.
  3. "Zoledronic Acid". The American Society of Health-System Pharmacists. Retrieved8 December 2017.
  4. "PRESS RELEASE: Novartis's Reclast Receives FDA Approval FOR Women With Postmenopausal Osteoporosis". FierceBiotech. Retrieved2021-09-02.
  5. Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 524. ISBN 9783527607495.
  6. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  7. National Prescribing Service (2009). "Zoledronic Acid for Osteoporosis". Medicines Update, Available at "Archived copy". Archived from the original on April 23, 2010. RetrievedJanuary 20, 2010.CS1 maint: archived copy as title (link)
  8. http://www.health.gov.il/units/pharmacy/trufot/alonim/533.pdf Zomera prescribing information
  9. Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, et al. (May 2005). "Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration". Br. J. Cancer. 92 (10): 1869–76. doi:10.1038/sj.bjc.6602551. PMC2361764. PMID 15870721.
  10. Dhillon, S. (2016). "Zoledronic Acid (Reclast®, Aclasta®): A Review in Osteoporosis". Drugs. 76 (17): 1683–1697. doi:10.1007/s40265-016-0662-4. PMID 27864686. S2CID 22079489.
  11. Lyles K, et al. (2007). "Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture". N. Engl. J. Med. 357 (18): 1799–809. doi:10.1056/NEJMoa074941. PMC2324066. PMID 17878149.
  12. "Biotech PRESS RELEASE: Novartis's Reclast Receives FDA Approval FOR Women With Postmenopausal Osteoporosis" (Press release). FierceBiotech, A Division of Questex A FierceMarkets Publication. August 20, 2007. Retrieved2018-03-27.
  13. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. (May 2007). "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis". N Engl J Med. 356 (18): 1809–22. doi:10.1056/nejmoa067312. PMID 17476007. S2CID 71443125.
  14. Dwan, K; Phillipi, CA; Steiner, RD; Basel, D (19 October 2016). "Bisphosphonate therapy for osteogenesis imperfecta". The Cochrane Database of Systematic Reviews. 10: CD005088. doi:10.1002/14651858.CD005088.pub4. PMC6611487. PMID 27760454.
  15. "Paget's Disease of Bone". www.rheumatology.org. Retrieved2015-07-09.
  16. Vondracek, S. F. (2010). "Managing osteoporosis in postmenopausal women". American Journal of Health-System Pharmacy. 67 (7 Suppl 3): S9–19. doi:10.2146/ajhp100076. PMID 20332498.
  17. "NPS MedicineWise"(PDF). Archived from the original(PDF) on 2016-03-04. Retrieved2014-01-25.
  18. "Zometa 4mg/5ml Concentrate for Solution for Infusion". medicines.org.uk. Archived from the original on 2010-02-24. Retrieved2010-02-24.
  19. "FDA Alert: Reclast (zoledronic acid): Drug Safety Communication - New Contraindication and Updated Warning on Kidney Impairment". drugs.com.
  20. "European Medicines Agency - Human medicines". europa.eu.
  21. Durie BG, Katz M, Crowley J (2005). "Osteonecrosis of the jaw and bisphosphonates". N. Engl. J. Med. 353 (1): 99–102, discussion 99–102. doi:10.1056/NEJM200507073530120. PMID 16000365.
  22. "European Medicines Agency - Human medicines". europa.eu.
  23. "Aclasta label- Australia"(PDF). Archived from the original(PDF) on 2016-03-04. Retrieved2014-01-25.
  24. D., Tripathi, K. (2013-09-30). Essentials of medical pharmacology (Seventh ed.). New Delhi. ISBN 9789350259375. OCLC 868299888.
  25. Koto K, Murata H, Kimura S, et al. (July 2010). "Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents". Oncol. Rep. 24 (1): 233–9. doi:10.3892/or_00000851. PMID 20514467.
  26. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ (2002). "Intravenous zoledronic acid in postmenopausal women with low bone mineral density". N. Engl. J. Med. 346 (9): 653–61. doi:10.1056/NEJMoa011807. PMID 11870242.
  27. Misra, Juhi; Mohanty, Sindhu T.; Madan, Sanjeev; Fernandes, James A.; Hal Ebetino, F.; Russell, R. Graham G.; Bellantuono, Ilaria (2016). "Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function". Stem Cells. 34 (3): 756–767. doi:10.1002/stem.2255. PMC4832316. PMID 26679354.
  28. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, et al. (February 2009). "Endocrine therapy plus zoledronic acid in premenopausal breast cancer". N. Engl. J. Med. 360 (7): 679–91. doi:10.1056/NEJMoa0806285. PMID 19213681.
  29. Coleman RE, Winter MC, Cameron D, et al. (March 2010). "The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer". Br. J. Cancer. 102 (7): 1099–105. doi:10.1038/sj.bjc.6605604. PMC2853093. PMID 20234364.
  30. Brufsky A, Bundred N, Coleman R, et al. (May 2008). "Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole". Oncologist. 13 (5): 503–14. doi:10.1634/theoncologist.2007-0206. PMID 18515735.
  31. Tonyali O, Arslan C, Altundag K (November 2010). "The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives". Expert Opin Pharmacother. 11 (16): 2715–25. doi:10.1517/14656566.2010.523699. PMID 20977404. S2CID 26073229.
  32. Delea TE, Taneja C, Sofrygin O, Kaura S, Gnant M (August 2010). "Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer". Clin. Breast Cancer. 10 (4): 267–74. doi:10.3816/CBC.2010.n.034. PMID 20705558.

Zoledronic acid
Zoledronic acid Language Watch Edit 160 160 Redirected from Zoledronate Zoledronic acid also known as zoledronate and sold under the brand name Zometa 4 by Novartis among others is a medication used to treat a number of bone diseases 3 These include osteoporosis high blood calcium due to cancer bone breakdown due to cancer Paget s disease of bone 3 and Duchenne muscular dystrophy DMD It is given by injection into a vein 3 Zoledronic acidClinical dataTrade namesReclast Zometa others 1 Other nameszoledronateAHFS Drugs comMonographMedlinePlusa605023License dataEU EMA by INN US DailyMed Zoledronic acid US FDA Zoledronic acidPregnancy categoryAU B3 2 Routes of administrationIntravenousDrug classBisphosphonate 3 ATC codeM05BA08 WHO Legal statusLegal statusUS only EU Rx onlyPharmacokinetic dataProtein binding22 MetabolismNilElimination half life146 hoursExcretionKidney partial IdentifiersIUPAC name 1 hydroxy 2 1H imidazol 1 yl ethane 1 1 diyl bis phosphonic acid CAS Number118072 93 8PubChem CID68740IUPHAR BPS3177DrugBankDB00399ChemSpider61986UNII70HZ18PH24KEGGD08689 ND01968 NChEBICHEBI 46557ChEMBLChEMBL924 YPDB ligandZOL PDBe RCSB PDB CompTox Dashboard EPA DTXSID0042668Chemical and physical dataFormulaC 5H 10N 2O 7P 2Molar mass272 090 g mol 13D model JSmol Interactive imageSMILES O P O O C O Cn1ccnc1 P O O OInChI InChI 1S C5H10N2O7P2 c8 5 15 9 10 11 16 12 13 14 3 7 2 1 6 4 7 h1 2 4 8H 3H2 H2 9 10 11 H2 12 13 14 Key XRASPMIURGNCCH UHFFFAOYSA N N Y what is this verify Common side effects include fever joint pain high blood pressure diarrhea and feeling tired 3 Serious side effects may include kidney problems low blood calcium and osteonecrosis of the jaw 3 Use during pregnancy may result in harm to the baby 3 It is in the bisphosphonate family of medications 3 It works by blocking the activity of osteoclast cells and thus decreases the breakdown of bone 3 Zoledronic acid was patented in 1986 and approved for medical use in the United States in 2001 3 5 It is on the World Health Organization s List of Essential Medicines 6 Contents 1 Medical uses 1 1 Bone complications of cancer 1 2 Osteoporosis 1 3 Other 2 Contraindications 3 Side effects 3 1 Kidneys 3 2 Bone 3 2 1 Osteonecrosis of the jaw 3 2 2 Atypical fractures 4 Pharmacology 5 Research 5 1 With hormone therapy for breast cancer 6 References 7 External linksMedical uses EditBone complications of cancer Edit Zoledronic acid is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer as well as for treating osteoporosis 7 It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases 8 It can be given at home rather than in hospital Such use has shown safety and quality of life benefits in people with breast cancer and bone metastases 9 Osteoporosis Edit Zoledronic acid in brand name products Aclasta and Reclast among others 10 may be given as a 5 mg infusion once per year for treatment of osteoporosis in men and post menopausal women at increased risk of fracture 11 In 2007 the U S Food and Drug Administration FDA also approved it for the treatment of postmenopausal osteoporosis 12 13 Other Edit Zoledronic acid may be used for treatment of osteogenesis imperfecta 14 A single 5 mg dose of zoledronic acid is used for the treatment of Paget s disease The template below is included via a redirect Template Mcn that has been nominated for discussion See redirects for discussion to help reach a consensus on what to do medical citation needed 15 Contraindications EditPoor renal function e g CrCl lt 30 mL min 16 Hypocalcaemia Pregnancy ParalysisSide effects EditSide effects can include fatigue anemia muscle aches fever and or swelling in the feet or legs Flu like symptoms are common after the first infusion although not subsequent infusions and are thought to occur because of its potential to activate human gd T cells gamma delta T cells Kidneys Edit There is a risk of severe renal impairment Appropriate hydration is important prior to administration as is adequate calcium and vitamin D intake prior to Aclasta therapy in patients with preexisting hypocalcaemia and for ten days following Aclasta in patients with Paget s disease of the bone Monitoring for other mineral metabolism disorders and the avoidance of invasive dental procedures for those who develop osteonecrosis of the jaw is recommended 17 Zoledronate is rapidly processed via the kidneys consequently its administration is not recommended for patients with reduced renal function or kidney disease 18 Some cases of acute kidney injury either requiring dialysis or having a fatal outcome following Reclast use have been reported to the U S Food and Drug Administration FDA 19 This assessment was confirmed by the European Medicines Agency EMA whose Committee for Medicinal Products for Human Use CHMP specified new contraindications for the medication on 15 December 2011 which include hypocalcaemia and severe renal impairment with a creatinine clearance of less than 35 ml min 20 Bone Edit Osteonecrosis of the jaw Edit A rare complication that has been recently observed in cancer patients being treated with bisphosphonates is osteonecrosis of the jaw This has mainly been seen in patients with multiple myeloma treated with zoledronic acid who have had dental extractions 21 Atypical fractures Edit After approving the drug on 8 July 2009 the European Medicines Agency conducted a class review of all bisphosphonates including zoledronic acid after several cases of atypical fractures were reported 22 In 2008 the EMA s Pharmacovigilance Working Party PhVWP noted that alendronic acid was associated with an increased risk of atypical fracture of the femur that developed with low or no trauma In April 2010 the PhVWP noted that further data from both the published literature and post marketing reports were now available which suggested that atypical stress fractures of the femur may be a class effect The European Medicines Agency then reviewed all case reports of stress fractures in patients treated with bisphosphonates relevant data from the published literature and data provided by the companies which market bisphosphonates The Agency recommended that doctors who prescribe bisphosphonate containing medicines should be aware that atypical fractures may occur rarely in the femur especially after long term use and that doctors who are prescribing these medicines for the prevention or treatment of osteoporosis should regularly review the need for continued treatment especially after five or more years of use 22 Pharmacology EditZoledronic acid slows down bone resorption allowing the bone forming cells time to rebuild normal bone and allowing bone remodeling 23 Relative potency 24 Bisphosphonate Relative potencyEtidronate 1Tiludronate 10Pamidronate 100Alendronate 100 500Ibandronate 500 1000Risedronate 1000Zoledronate 5000Research EditZoledronic acid has been found to have a direct antitumor effect and to synergistically augment the effects of other antitumor agents in osteosarcoma cells 25 Zoledronic acid has shown significant benefits versus placebo over three years with a reduced number of vertebral fractures and improved markers of bone density 26 13 An annual dose of zoledronic acid may also prevent recurring fractures in patients with a previous hip fracture 11 Zoledronic acid also attenuates accumulation of DNA damage in mesenchymal stem cells and protects their function 27 With hormone therapy for breast cancer Edit An increase in disease free survival DFS was found in the ABCSG 12 trial in which 1 803 premenopausal women with endocrine responsive early breast cancer received anastrozole with zoledronic acid 28 A retrospective analysis of the AZURE trial data revealed a DFS survival advantage particularly where estrogen had been reduced 29 In a meta analysis of trials where upfront zoledronic acid was given to prevent aromatase inhibitor associated bone loss active cancer recurrence appeared to be reduced 30 As of 2010 update The results of clinical studies of adjuvant treatment on early stage hormone receptor positive breast cancer patients under hormonal treatment especially with the bisphosphonate zoledronic acid caused excitement because they demonstrated an additive effect on decreasing disease relapses at bone or other sites A number of clinical and in vitro and in vivo preclinical studies which are either ongoing or have just ended are investigating the mechanism of action and antitumoral activity of bisphosphonates 31 A 2010 review concluded that adding zoledronic acid 4 mg intravenously every 6 months to endocrine therapy in premenopausal women with hormone receptor positive early breast cancer is cost effective from a US health care system perspective 32 References Edit Drugs com International trade names for zoledronic acid Page accessed Jan 14 2015 a b Zoledronic acid Use During Pregnancy Drugs com 1 June 2020 Retrieved 19 October 2020 a b c d e f g h i j Zoledronic Acid The American Society of Health System Pharmacists Retrieved 8 December 2017 PRESS RELEASE Novartis s Reclast Receives FDA Approval FOR Women With Postmenopausal Osteoporosis FierceBiotech Retrieved 2021 09 02 Fischer Jnos Ganellin C Robin 2006 Analogue based Drug Discovery John Wiley amp Sons p 524 ISBN 9783527607495 World Health Organization 2019 World Health Organization model list of essential medicines 21st list 2019 Geneva World Health Organization hdl 10665 325771 WHO MVP EMP IAU 2019 06 License CC BY NC SA 3 0 IGO National Prescribing Service 2009 Zoledronic Acid for Osteoporosis Medicines Update Available at Archived copy Archived from the original on April 23 2010 Retrieved January 20 2010 CS1 maint archived copy as title link http www health gov il units pharmacy trufot alonim 533 pdf Zomera prescribing information Wardley A Davidson N Barrett Lee P Hong A Mansi J Dodwell D et al May 2005 Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases a randomised crossover study of community vs hospital bisphosphonate administration Br J Cancer 92 10 1869 76 doi 10 1038 sj bjc 6602551 PMC 2361764 PMID 15870721 Dhillon S 2016 Zoledronic Acid Reclast Aclasta A Review in Osteoporosis Drugs 76 17 1683 1697 doi 10 1007 s40265 016 0662 4 PMID 27864686 S2CID 22079489 a b Lyles K et al 2007 Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture N Engl J Med 357 18 1799 809 doi 10 1056 NEJMoa074941 PMC 2324066 PMID 17878149 Biotech PRESS RELEASE Novartis s Reclast Receives FDA Approval FOR Women With Postmenopausal Osteoporosis Press release FierceBiotech A Division of Questex A FierceMarkets Publication August 20 2007 Retrieved 2018 03 27 a b Black DM Delmas PD Eastell R Reid IR Boonen S Cauley JA et al May 2007 Once yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 18 1809 22 doi 10 1056 nejmoa067312 PMID 17476007 S2CID 71443125 Dwan K Phillipi CA Steiner RD Basel D 19 October 2016 Bisphosphonate therapy for osteogenesis imperfecta The Cochrane Database of Systematic Reviews 10 CD005088 doi 10 1002 14651858 CD005088 pub4 PMC 6611487 PMID 27760454 Paget s Disease of Bone www rheumatology org Retrieved 2015 07 09 Vondracek S F 2010 Managing osteoporosis in postmenopausal women American Journal of Health System Pharmacy 67 7 Suppl 3 S9 19 doi 10 2146 ajhp100076 PMID 20332498 NPS MedicineWise PDF Archived from the original PDF on 2016 03 04 Retrieved 2014 01 25 Zometa 4mg 5ml Concentrate for Solution for Infusion medicines org uk Archived from the original on 2010 02 24 Retrieved 2010 02 24 FDA Alert Reclast zoledronic acid Drug Safety Communication New Contraindication and Updated Warning on Kidney Impairment drugs com European Medicines Agency Human medicines europa eu Durie BG Katz M Crowley J 2005 Osteonecrosis of the jaw and bisphosphonates N Engl J Med 353 1 99 102 discussion 99 102 doi 10 1056 NEJM200507073530120 PMID 16000365 a b European Medicines Agency Human medicines europa eu Aclasta label Australia PDF Archived from the original PDF on 2016 03 04 Retrieved 2014 01 25 D Tripathi K 2013 09 30 Essentials of medical pharmacology Seventh ed New Delhi ISBN 9789350259375 OCLC 868299888 Koto K Murata H Kimura S et al July 2010 Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis and shows combined effects with other anticancer agents Oncol Rep 24 1 233 9 doi 10 3892 or 00000851 PMID 20514467 Reid IR Brown JP Burckhardt P Horowitz Z Richardson P Trechsel U Widmer A Devogelaer JP Kaufman JM Jaeger P Body JJ Brandi ML Broell J Di Micco R Genazzani AR Felsenberg D Happ J Hooper MJ Ittner J Leb G Mallmin H Murray T Ortolani S Rubinacci A Saaf M Samsioe G Verbruggen L Meunier PJ 2002 Intravenous zoledronic acid in postmenopausal women with low bone mineral density N Engl J Med 346 9 653 61 doi 10 1056 NEJMoa011807 PMID 11870242 Misra Juhi Mohanty Sindhu T Madan Sanjeev Fernandes James A Hal Ebetino F Russell R Graham G Bellantuono Ilaria 2016 Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function Stem Cells 34 3 756 767 doi 10 1002 stem 2255 PMC 4832316 PMID 26679354 Gnant M Mlineritsch B Schippinger W Luschin Ebengreuth G Postlberger S Menzel C et al February 2009 Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 7 679 91 doi 10 1056 NEJMoa0806285 PMID 19213681 Coleman RE Winter MC Cameron D et al March 2010 The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response exploratory evidence for direct anti tumour activity in breast cancer Br J Cancer 102 7 1099 105 doi 10 1038 sj bjc 6605604 PMC 2853093 PMID 20234364 Brufsky A Bundred N Coleman R et al May 2008 Integrated analysis of zoledronic acid for prevention of aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole Oncologist 13 5 503 14 doi 10 1634 theoncologist 2007 0206 PMID 18515735 Tonyali O Arslan C Altundag K November 2010 The role of zoledronic acid in the adjuvant treatment of breast cancer current perspectives Expert Opin Pharmacother 11 16 2715 25 doi 10 1517 14656566 2010 523699 PMID 20977404 S2CID 26073229 Delea TE Taneja C Sofrygin O Kaura S Gnant M August 2010 Cost effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone responsive early breast cancer Clin Breast Cancer 10 4 267 74 doi 10 3816 CBC 2010 n 034 PMID 20705558 External links Edit Zoledronic acid Drug Information Portal U S National Library of Medicine Medicine portal Retrieved from https en wikipedia org w index php title Zoledronic acid amp oldid 1052639368, wikipedia, wiki, book,

books

, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.